Design and synthesis of 4th generation EGFR inhibitors against human triple (Del19/T790M/C797S) mutation. 2023

Jiyoung Jeon, and Sun Young Jang, and Eun Joo Kwak, and Sun Hoe Lee, and Joo-Yun Byun, and Yu-Yon Kim, and Young Gil Ahn, and Pargat Singh, and Kyeongwon Moon, and In Su Kim
School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea; Hanmi Research Center, Hanmi Pharmaceutical Co., Ltd., Hwaseong, 18469, Republic of Korea.

Epidermal growth factor receptor (EGFR)-targeted therapy is used to treat EGFR mutation-induced non-small cell lung cancer (NSCLC). However, its efficacy does not last beyond a certain period due to the development of primary and secondary resistance. First and second-generation inhibitors (e.g., gefitinib, erlotinib, and afatinib) induce EGFR T790M mutations, while third-generation inhibitors (e.g., osimertinib) induce C797S as a major target resistance mutation. Therefore, the C797S mutation is being actively researched. In this study, we investigated the structure-activity relationship of several synthesized compounds as fourth-generation inhibitors against the C797S mutation. We identified a compound 13k that displayed nanomolar potency and high selectivity. Moreover, we used a triple mutant xenograft mouse model to evaluate the in vivo efficacy of 13k in inhibiting EGFR C797S, which demonstrated exceptional profiles and satisfactory EGFR C797S inhibition efficacy. Based on its excellent in vitro and in vivo profiles, compound 13k can be considered a promising candidate for treating EGFR C797S mutations.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000814 Aniline Compounds Compounds that include the aminobenzene structure. Phenylamine,Phenylamines,Anilines,Compounds, Aniline
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D019008 Drug Resistance, Neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. Antibiotic Resistance, Neoplasm,Antineoplastic Drug Resistance,Drug Resistance, Antineoplastic,Antineoplastic Agent Resistance,Neoplasm Drug Resistance,Resistance, Antineoplastic Agent,Resistance, Antineoplastic Drug
D066246 ErbB Receptors A family of structurally related cell-surface receptors that signal through an intrinsic PROTEIN-TYROSINE KINASE. The receptors are activated upon binding of specific ligands which include EPIDERMAL GROWTH FACTORS, and NEUREGULINS. EGF Receptor,Epidermal Growth Factor Receptor,Epidermal Growth Factor Receptor Family Protein,Epidermal Growth Factor Receptor Protein-Tyrosine Kinase,ErbB Receptor,HER Family Receptor,Receptor, EGF,Receptor, Epidermal Growth Factor,Receptor, TGF-alpha,Receptor, Transforming-Growth Factor alpha,Receptor, Urogastrone,Receptors, Epidermal Growth Factor-Urogastrone,TGF-alpha Receptor,Transforming Growth Factor alpha Receptor,Urogastrone Receptor,c-erbB-1 Protein,erbB-1 Proto-Oncogene Protein,EGF Receptors,Epidermal Growth Factor Receptor Family Proteins,Epidermal Growth Factor Receptor Kinase,HER Family Receptors,Proto-oncogene c-ErbB-1 Protein,Receptor Tyrosine-protein Kinase erbB-1,Receptor, ErbB-1,Receptors, Epidermal Growth Factor,Epidermal Growth Factor Receptor Protein Tyrosine Kinase,ErbB-1 Receptor,Family Receptor, HER,Family Receptors, HER,Proto oncogene c ErbB 1 Protein,Proto-Oncogene Protein, erbB-1,Receptor Tyrosine protein Kinase erbB 1,Receptor, ErbB,Receptor, ErbB 1,Receptor, HER Family,Receptor, TGF alpha,Receptor, Transforming Growth Factor alpha,Receptors, EGF,Receptors, Epidermal Growth Factor Urogastrone,Receptors, ErbB,Receptors, HER Family,c erbB 1 Protein,c-ErbB-1 Protein, Proto-oncogene,erbB 1 Proto Oncogene Protein

Related Publications

Jiyoung Jeon, and Sun Young Jang, and Eun Joo Kwak, and Sun Hoe Lee, and Joo-Yun Byun, and Yu-Yon Kim, and Young Gil Ahn, and Pargat Singh, and Kyeongwon Moon, and In Su Kim
February 2022, ACS medicinal chemistry letters,
Jiyoung Jeon, and Sun Young Jang, and Eun Joo Kwak, and Sun Hoe Lee, and Joo-Yun Byun, and Yu-Yon Kim, and Young Gil Ahn, and Pargat Singh, and Kyeongwon Moon, and In Su Kim
November 2020, Molecular cancer therapeutics,
Jiyoung Jeon, and Sun Young Jang, and Eun Joo Kwak, and Sun Hoe Lee, and Joo-Yun Byun, and Yu-Yon Kim, and Young Gil Ahn, and Pargat Singh, and Kyeongwon Moon, and In Su Kim
August 2020, Bioorganic & medicinal chemistry letters,
Jiyoung Jeon, and Sun Young Jang, and Eun Joo Kwak, and Sun Hoe Lee, and Joo-Yun Byun, and Yu-Yon Kim, and Young Gil Ahn, and Pargat Singh, and Kyeongwon Moon, and In Su Kim
September 2022, Bioorganic & medicinal chemistry letters,
Jiyoung Jeon, and Sun Young Jang, and Eun Joo Kwak, and Sun Hoe Lee, and Joo-Yun Byun, and Yu-Yon Kim, and Young Gil Ahn, and Pargat Singh, and Kyeongwon Moon, and In Su Kim
September 2021, Journal of biomolecular structure & dynamics,
Jiyoung Jeon, and Sun Young Jang, and Eun Joo Kwak, and Sun Hoe Lee, and Joo-Yun Byun, and Yu-Yon Kim, and Young Gil Ahn, and Pargat Singh, and Kyeongwon Moon, and In Su Kim
July 2016, Journal of hematology & oncology,
Jiyoung Jeon, and Sun Young Jang, and Eun Joo Kwak, and Sun Hoe Lee, and Joo-Yun Byun, and Yu-Yon Kim, and Young Gil Ahn, and Pargat Singh, and Kyeongwon Moon, and In Su Kim
June 2016, Nature,
Jiyoung Jeon, and Sun Young Jang, and Eun Joo Kwak, and Sun Hoe Lee, and Joo-Yun Byun, and Yu-Yon Kim, and Young Gil Ahn, and Pargat Singh, and Kyeongwon Moon, and In Su Kim
January 2017, Cancer letters,
Jiyoung Jeon, and Sun Young Jang, and Eun Joo Kwak, and Sun Hoe Lee, and Joo-Yun Byun, and Yu-Yon Kim, and Young Gil Ahn, and Pargat Singh, and Kyeongwon Moon, and In Su Kim
May 2024, Journal of medicinal chemistry,
Jiyoung Jeon, and Sun Young Jang, and Eun Joo Kwak, and Sun Hoe Lee, and Joo-Yun Byun, and Yu-Yon Kim, and Young Gil Ahn, and Pargat Singh, and Kyeongwon Moon, and In Su Kim
November 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Copied contents to your clipboard!